Problems using the defined daily dose (DDD) as statistical basis for drug pricing and reimbursement (2007)
Related news and resources
Collaborating for Global Health Progress flyer
Discover how the innovative pharmaceutical industry works with partners to advance the SDGs
Read more
WHO Intergovernmental Negotiating Body (INB) intersessional briefing on “Access and benefit sharing”
On 22 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 10: WHO Pathogen Access and Benefit Sharing System, with the Pandemic Influenza Preparedness Framework as an example” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).
Read moreWHO Intergovernmental Negotiating Body (INB) intersessional briefing on the “Sustainable and equitably distributed production”
On 20 March, IFPMA delivered a shortened version of the below statement at the WHO INB intersessional briefing on “Article 7: Access to technology: promoting sustainable and equitably distributed production sustainable and equitably distributed production and transfer of technology and know-how” of the WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response (“WHO CA+”).
Read more